Therapeutic use nsg33 growth factor.

Use of i) an isolated polypeptide comprising a) an amino acid sequence consisting of SEQ ID No. 4; b) a biologically active variant sequence of the amino acid sequence, wherein the variant has at least 70% sequence identity with said SEQ ID No. 4; or c) a biologically active fragment of at least 50 contiguous amino acids of any of a) to b), said fragment having at least 70% sequence identity with SEQ ID No. 4 in a range of overlap of at least 50 amino acids wherein the biological activity is neuroprotection, survival of neurons, neurogenesis and / or proliferation of neuronal precursors, ii) an isolated nucleic acid sequence encoding a polypeptide as defined in i) or a nucleic acid is a sequence complementary to a sequence encoding a polypeptide as defined in i), iii) an expression vector comprising the nucleic acid sequence as defined in ii), iv) a composition of host cells, wherein said cells are transformed or transduced with the vector as defined under iii), provided that the use of human embryos for industrial or commercial purposes include, v) a line cel ssrooms packaging comprising the nucleic acid sequence as defined in ii), or vi) an implantable biocompatible cell, wherein said device comprises: a) a semipermeable membrane permitting the diffusion of a polypeptide as defined in i) and / or a viral vector; b) a composition of cells as that defined in iv), or a line packaging cell as defined in v), for the preparation of a medicament, is wherein said medicament is for treating a disease, disorder or nervous system damage, where they are lost or damaged neural cells.